Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10376319" target="_blank" >RIV/00216208:11130/18:10376319 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/18:10376319
Result on the web
<a href="https://doi.org/10.1038/s41416-018-0098-6" target="_blank" >https://doi.org/10.1038/s41416-018-0098-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41416-018-0098-6" target="_blank" >10.1038/s41416-018-0098-6</a>
Alternative languages
Result language
angličtina
Original language name
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
Original language description
BACKGROUND: In neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA), occasionally shows intratumoural heterogeneity (ITH), i.e. coexistence of MYCN-amplified and non-MYCN-amplified tumour cell clones, called heterogeneous MNA (hetMNA). Prognostication and therapy allocation are still unsolved issues. METHODS: The SIOPEN Biology group analysed 99 hetMNA NBs focussing on the prognostic significance of MYCN ITH. RESULTS: Patients <18 months (18 m) showed a better outcome in all stages as compared to older patients (5-year OS in localised stages: <18 m: 0.95 +/- 0.04, >18 m: 0.67 +/- 0.14, p = 0.011; metastatic: <18 m: 0.76 +/- 0.15, >18 m: 0.28 +/- 0.09, p = 0.084). The genomic 'background', but not MNA clone sizes, correlated significantly with relapse frequency and OS. No relapses occurred in cases of only numerical chromosomal aberrations. Infiltrated bone marrows and relapse tumour cells mostly displayed no MNA. However, one stage 4s tumour with segmental chromosomal aberrations showed a homogeneous MNA in the relapse. CONCLUSIONS: This study provides a rationale for the necessary distinction between heterogeneous and homogeneous MNA. HetMNA tumours have to be evaluated individually, taking age, stage and, most importantly, genomic background into account to avoid unnecessary upgrading of risk/overtreatment, especially in infants, as well as in order to identify tumours prone to developing homogeneous MNA.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Cancer
ISSN
0007-0920
e-ISSN
—
Volume of the periodical
118
Issue of the periodical within the volume
11
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
1502-1512
UT code for WoS article
000435643900012
EID of the result in the Scopus database
2-s2.0-85046792055